This stands in contrast to a second-generation NAMPT inhibitor, OT-82, which is also effective against multiple leukemias, but more cytotoxic in cells with higher NAPRT expression [36], and requires a reduction of dietary nicotinic acid to improve the therapeutic index against leukemia in vivo [37], a strategy which may be limited by patient adherence. Here, NAPRT is linked to leukemia.